Nektar Therapeutics
Il-2R.beta.-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

Abstract:

The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R.beta.-activating amount of a long acting, IL-2R.beta.-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.